SLDB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
57.7M
+0.5%
57.4M
+0.1%
57.3M
+16.0%
49.4M
+2.8%
48.1M
R&D
43.6M
-1.5%
44.3M
-4.1%
46.1M
+21.0%
38.1M
-1.9%
38.9M
SG&A
14.1M
+7.2%
13.1M
+17.5%
11.2M
-0.9%
11.3M
+22.5%
9.2M
Operating Income
-57655000
-0.5%
-57384000
-0.1%
-57308000
-16.0%
-49403000
-2.8%
-48058000
EBITDA
-57239000
-0.4%
-56993000
-0.1%
-56913000
-16.3%
-48936000
-2.6%
-47682000
Net Income
-53948000
+1.6%
-54799000
+3.4%
-56737000
-14.0%
-49787000
-8.8%
-45776000
EPS (Basic)
$-0.36
+5.3%
$-0.38
+26.9%
$-0.52
+0.0%
$-0.52
-8.3%
$-0.48
EPS (Diluted)
$-0.36
+5.3%
$-0.38
+26.9%
$-0.52
+0.0%
$-0.52
-8.3%
$-0.48
Shares (Diluted)
151.0M
+5.1%
143.7M
+30.9%
109.8M
+15.4%
95.1M
+0.7%
94.4M
Solid Biosciences (SLDB) — Financials